Clinical Trials | January 14, 2026
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Subscribe To Our Newsletter & Stay Updated
